Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

New Drug Update for The Week Ending July 6

7/8/2019

 
Regulatory Update

The FDA approved Karyopharm Therapeutics’ selinexor (Xpovio), 
on 7/3/2019, in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and a CD38-targeted monoclonal antibody. In February 2019, the FDA Oncologic Drugs Advisory Committee recommend a delay in approval of selinexor-dexamethasone until after the results of the Phase III BOSTON trial were available in the first half of 2020. In March 2019, the FDA delayed the PDUFA date for selinexor by three months.

The FDA accepted the NDA for RedHill Biopharma's RHB-105 (Talicia) 
for the treatment of H. pylori infection and assigned a November 2, 2019 PDUFA date. RHB-105 is a combination of rifabutin, amoxicillin and omeprazole

Gilead plans to file an NDA 
for filgotinib by the end of 2019, for the treatment of Crohn's disease, rheumatoid arthritis, and Ankylosing spondylitis

Announced Research Updates


Boston Biomedical discontinued a Phase III trial 
when an interim analysis found no improvement when adding napabucasin to nab-paclitaxel with gemcitabine compared to the two drugs alone in the treatment of metastatic pancreatic ductal adenocarcinoma.

Lilly announced that a targeted investigation 
examining patients with cardiovascular (CV) risk factors that participated in the lasmiditan SPARTAN and SAMURAI trials found a small increase in palpitations or tachycardia as the only CV ADR, however it could not be determined if the increase was due to lasmiditan. The presence of CV risk factors did not affect efficacy. 

TG Therapeutics announced 
that in a 48-week, 48 patient, Phase II trial, 99% of patients treated with ublituximab achieved at least a 99% reduction in peripheral CD19+ B cells at 4 weeks, which was maintained through 48 weeks. At 48 weeks the annualized relapse was 0.07, down from a mean 1.45 relapses per year before the trial. 93% of patients were relapse free.

Published Research Updates


In a 16-week, 696 patient, Phase III trial, where compared to placebo, treatment with tanezumab decreased the WOMAC pain score by 0.6 points with 2.5mg in week 1 and 8 and a 0.73 decrease with 2.5 mg given in week 1 and 5 mg given in week 8 in patients with osteoarthritis pain of the knee and hip and an inadequate response to standard analgesics. The WOMAC Physical Function score was decreased 0.66 points with 2.5 mg and 0.89 points with 2.5/5 mg.

In a 72 patient trial, levosimendan did not reduce the occurrence rate of acute kidney injury compared to milrinone in infants after open-heart surgery with cardiopulmonary bypass.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.